Cargando…
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer
The effects of pharmacological hypoxia-inducible factor (HIF) stabilization were investigated in the MMTV-Neu(ndl)-YD5 (NeuYD) mouse model of breast cancer. This study first confirmed the sensitivity of this model to increased vascular endothelial growth factor (VEGF), using bigenic NeuYD;MMTV-VEGF-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354531/ https://www.ncbi.nlm.nih.gov/pubmed/28331872 http://dx.doi.org/10.2147/HP.S130526 |
_version_ | 1782515327669633024 |
---|---|
author | Seeley, Todd W Sternlicht, Mark D Klaus, Stephen J Neff, Thomas B Liu, David Y |
author_facet | Seeley, Todd W Sternlicht, Mark D Klaus, Stephen J Neff, Thomas B Liu, David Y |
author_sort | Seeley, Todd W |
collection | PubMed |
description | The effects of pharmacological hypoxia-inducible factor (HIF) stabilization were investigated in the MMTV-Neu(ndl)-YD5 (NeuYD) mouse model of breast cancer. This study first confirmed the sensitivity of this model to increased vascular endothelial growth factor (VEGF), using bigenic NeuYD;MMTV-VEGF-25 mice. Tumor initiation was dramatically accelerated in bigenic animals. Bigenic tumors were also more aggressive, with shortened doubling times and increased lung metastasis as compared to NeuYD controls. In separate studies, NeuYD mice were treated three times weekly from 7 weeks of age until study end with two different HIF prolyl hydroxylase inhibitors (HIF-PHIs), FG-4497 or roxadustat (FG-4592). In NeuYD mice, HIF-PHI treatments elevated erythropoiesis markers, but no differences were detected in tumor onset or the phenotypes of established tumors. |
format | Online Article Text |
id | pubmed-5354531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53545312017-03-22 Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer Seeley, Todd W Sternlicht, Mark D Klaus, Stephen J Neff, Thomas B Liu, David Y Hypoxia (Auckl) Original Research The effects of pharmacological hypoxia-inducible factor (HIF) stabilization were investigated in the MMTV-Neu(ndl)-YD5 (NeuYD) mouse model of breast cancer. This study first confirmed the sensitivity of this model to increased vascular endothelial growth factor (VEGF), using bigenic NeuYD;MMTV-VEGF-25 mice. Tumor initiation was dramatically accelerated in bigenic animals. Bigenic tumors were also more aggressive, with shortened doubling times and increased lung metastasis as compared to NeuYD controls. In separate studies, NeuYD mice were treated three times weekly from 7 weeks of age until study end with two different HIF prolyl hydroxylase inhibitors (HIF-PHIs), FG-4497 or roxadustat (FG-4592). In NeuYD mice, HIF-PHI treatments elevated erythropoiesis markers, but no differences were detected in tumor onset or the phenotypes of established tumors. Dove Medical Press 2017-03-10 /pmc/articles/PMC5354531/ /pubmed/28331872 http://dx.doi.org/10.2147/HP.S130526 Text en © 2017 Seeley et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Seeley, Todd W Sternlicht, Mark D Klaus, Stephen J Neff, Thomas B Liu, David Y Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title | Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title_full | Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title_fullStr | Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title_full_unstemmed | Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title_short | Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer |
title_sort | induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a vegf-sensitive model of spontaneous breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354531/ https://www.ncbi.nlm.nih.gov/pubmed/28331872 http://dx.doi.org/10.2147/HP.S130526 |
work_keys_str_mv | AT seeleytoddw inductionoferythropoiesisbyhypoxiainduciblefactorprolylhydroxylaseinhibitorswithoutpromotionoftumorinitiationprogressionormetastasisinavegfsensitivemodelofspontaneousbreastcancer AT sternlichtmarkd inductionoferythropoiesisbyhypoxiainduciblefactorprolylhydroxylaseinhibitorswithoutpromotionoftumorinitiationprogressionormetastasisinavegfsensitivemodelofspontaneousbreastcancer AT klausstephenj inductionoferythropoiesisbyhypoxiainduciblefactorprolylhydroxylaseinhibitorswithoutpromotionoftumorinitiationprogressionormetastasisinavegfsensitivemodelofspontaneousbreastcancer AT neffthomasb inductionoferythropoiesisbyhypoxiainduciblefactorprolylhydroxylaseinhibitorswithoutpromotionoftumorinitiationprogressionormetastasisinavegfsensitivemodelofspontaneousbreastcancer AT liudavidy inductionoferythropoiesisbyhypoxiainduciblefactorprolylhydroxylaseinhibitorswithoutpromotionoftumorinitiationprogressionormetastasisinavegfsensitivemodelofspontaneousbreastcancer |